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Endothelial function and BRS were 
both well preserved in mild OSA.  
Nasal resistance improved more in 
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ABSTRACT 
 
Obstructive sleep apnea (OSA) is a chronic, progressive disease. OSA is associated with 
increased cardiovascular morbidity and mortality, the risk being more frequently 
encountered with severe degrees of OSA. Endothelial dysfunction, increased sympathetic 
activation and impaired cardiac autonomic control as reflected by depressed baroreflex 
sensitivity (BRS) are possible mechanisms involved in the cardiovascular complications of 
OSA. Obesity is a major risk factor for OSA and therefore weight loss is considered an 
effective treatment for OSA in overweight patients. Some patients, however, do not benefit 
from weight loss. It has been postulated that nasal obstruction may act as an independent 
risk factor for OSA. 
The present study includes a prospective randomized study and a cross sectional 
comparison study. The prospective randomized study explored the effects of a 1-year 
supervised lifestyle intervention with weight reduction on endothelial function and 
evaluated whether impaired nasal airflow might explain the missing effect of weight 
reduction on OSA.  The aim of the cross sectional part of the study was to determine 
whether endothelial dysfunction and depressed BRS existed in mild OSA patients when 
compared to their age, body mass index and sex matched subjects without OSA. 
Endothelial function was measured by brachial artery flow-mediated dilatation (FMD), 
change in nasal resistance was measured by rhinomanometer and the phenylephrine test 
was used to measure the BRS. 
This study showed that cardiovascular risk factors, atleast in terms of  FMD and BRS, are 
not icreased in mild OSA patients when compared to their non-OSA countersubjects. 1 year 
lifestyle intervention with weight reduction resulted in improved AHI and other obesity 
related risk factors for cardiovascular diseases although no improvement in FMD was 
detected. Nasal resistance reduced significantly more in patients who had been cured from 
OSA and smoking had a negative impact on both nasal resistance and improvement of 
AHI. 
Although in mild OSA endothelial function and BRS are still preserved, lifestyle 
intervention with weight reduction did achieve an improvement in other obesity related 
risk factors for cardiovascular diseases, thus highlighting the importance of early 
intervention. In addition impaired nasal breathing and smoking may prevent the beneficial 
effects of weight reduction in the treatment of OSA.  
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TIIVISTELMÄ 
 
Obstruktiivinen uniapnea on krooninen ja etenevä sairaus, joka on yhdistetty 
suurentuneeseen sydän ja verisuonitautien kuolleisuuteen ja sairastavuuteen. Riski on 
yleisempi vaikea-asteisessa taudissa. Endoteelin toimintahäiriö, suurentunut sympaattisen 
hermoston aktiivisuus ja häiriintynyt sydämen autonominen kontrolli, joka määritetään 
baroheijasteherkkyyden (BRS) avulla, ovat mahdollisia mekanismeja uniapnean 
liitännäissairauksien, kuten sydän ja verisuonisairauksien synnyssä. Lihavuus on suurin 
riskitekijä obstruktiiviselle uniapnealle ja siksi painopudotusta onkin pidetty tehokkaana 
uniapnean hoitomuotona ylipainoisille potilaille. Jotkut potilaat eivät kuitenkaan hyödy 
painonpudotuksesta. Nenän tukkoisuutta on pidetty yhtenä uniapnean itsenäisenä 
riskitekijänä. 
Tutkimuksemme koostui prospektiivisesta satunnaistetusta seurantatutkimuksesta ja 
läpileikkaustutkimuksesta. Satunnaistetussa seurantatutkimuksessa pyrimme selvittämään 
1-vuoden painonpudotukseen tähtäävän elämäntapaohjauksen vaikutuksia 
endoteelitoimintaan ja voisiko nenän lisääntynyt virtausvastus estää painonpudotuksen 
suotuisia vaikutuksia uniapnean hoidossa.  Läpileikkaustutkimuksessa selvitettiin 
eroavatko lievää uniapneaa sairastavien ja ikä, sukupuoli ja painoindeksivakioitujen 
uniapneaa sairastamattomien  verrokkien endoteelitoiminta ja baroheijasteherkkyys 
toisistaan. 
Tutkimustulokset osoittivat, että verrokkeihin verrattuna, leivässä obstruktiivisessa 
uniapneassa sydän ja verisuonitautien riskitekijät eivät ole ainakaan endoteelitoiminnan ja 
baroheijasteherkkyyden valossa kohonneet. Yhden vuoden painonpudotukseen johtanut 
elämäntapaohjaus paransi uniapneaa, apnea hyponea indeksiä, LDL-kolesterolipitoisuutta 
ja seerumin insuliinipitoisuutta, vaikka varsinaista parantumista ei endoteelitoiminnassa 
tapahtunut. Nenän virtausvastus väheni merkittävästi enemmän niillä, jotka parantuivat 
uniapneasta ja tupakointi lisäsi nenän virtausvastusta ja huononsi apnea hyponea indeksin 
paranemista elämäntapaohjauksen ja painonpudotuksen jälkeen. Vaikka lievässä 
uniapneassa endoteelitoiminta ja baroheijasteherkkyys eivät olleet vielä häiriintyneet, 
elämäntapaohjauksella saavutettu painonpudotus paransi muita lihavuuteen liittyviä 
riskitekijöitä sydän ja verisuonisairauksille. Täten varhaiseen interventioon tulisi pyrkiä. 
Lisäksi tukkoinen nenä ja tupakointi voivat estää painonpudotuksen parantavia 
vaikutuksia uniapnean hoidossa. Täten uniapneaa hoidettaessa on painonpudotuksen 
lisäksi hoidettava myös tukkoista nenää ja tarjota tupakkavieroitusta kaikille tupakoiville 
potilaille. 
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1 Introduction 
Obstructive sleep apnea (OSA) is a chronic disease which is characterized by frequent 
episodes of total and/or partial collapse of the upper airway during sleep, leading to 
recurrent episodes of hypoxia and arousals from sleep (Young et al. 1993). In adults, OSA 
affects approximately one out of every five men and one out of every ten females (Young et 
al. 1993, Duran et al. 2001). In recent reports in the literature, moderate to severe OSA has 
been recognized as an independent risk factor for cardiovascular disease (Floras 2014, 
Kendzerska et al. 2014, Nieto et al. 2000, Somers et al. 2008, Yaggi et al. 2005). However 
there are only a few studies which have investigated the association of mild OSA and 
cardiovascular disease. Since OSA has a natural tendency to worsen over time, particularly 
if there is an accompanying weight gain (Berger, Berger & Oksenberg 2009), early 
intervention is essential in order to prevent the serious co-morbidities, mainly in the form 
of cardiovascular disease. Weight reduction has been reported to be beneficial in most 
overweight patients with OSA (Tuomilehto et al. 2009, Foster et al. 2009, Johansson et al. 
2009). In mild OSA, the disease is at an early stage when it is most likely that the organ 
systems may still possess the capacity to fully recover from OSA-induced adverse 
metabolical and cardiovascular effects or at least, the progression of the disease may be 
prevented (Tuomilehto et al. 2009, Johansson et al. 2009). A deterioration of endothelial 
function and an impairment of baroreflex sensitivity (BRS) are the early signs of 
cardiovascular disease (Foster, Poulin & Hanly 2007, Priou et al. 2010, Bayram et al. 2009, 
Kato et al. 2000, Frattola et al. 1997, La Rovere et al. 1998, Mortara et al. 1997). The present 
work evaluated endothelial dysfunction and BRS to examine whether risk factors of 
cardiovascular disease were present in mild OSA when compared to matched snorers 
without OSA. In some patients, sleep apnea and the apnea hypopnea index (AHI) do not 
seem to improve even after successful weight loss. The present study also evaluated 
whether impaired nasal airway function explained a part of the missing effect of weight 
reduction. Therefore, in prospective randomized controlled trial, we evaluated whether 
lifestyle intervention with a very low calorie diet would achieve any improvement in the 
cardiovascular risk factors and furthermore could impaired nasal breathing prevent the 
positive effects of weight reduction.  
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2  Review of literature 
2.1 OBSTRUCTIVE SLEEP APNEA (OSA) 
2.1.1 Definitions and classification 
Obstructive sleep apnea has been defined by the American Academy of Sleep Medicine 
(AASM) as recurrent episodes of upper airway obstruction resulting in cessation (apnea) or 
reduction (hypopnea) in airway during sleep (Iber et al. 2007). Obstructive apnea is defined 
as a cessation of airflow for at least 10 seconds despite the breathing efforts. If one wish to 
score the apneas there must be a reduction of 90% or more in airflow from baseline but no 
desaturation of oxyhemoglobin is needed. The AASM 2007 Manual for Scoring Sleep and 
associated Events recommended that hypopnea should be defined as a 30% or more 
reduction in nasal pressure signal followed by > 4% desaturation. This manual included 
also an alternative definition for hypopnea, where hypopnea required that there should be 
a 50% or more reduction in nasal airflow associated with >3 desaturation or arousal (Iber et 
al. 2007). In addition, the new 2012 AASM guideline for hypopnea scoring requires that 
there is a decrease in airflow of >30% lasting >10 s, associated with either >3% desaturation 
or an arousal (Berry et al. 2012). The apnea-hypopnea index (AHI) is the sum of the 
hypopnea and apnea episodes in one hour of sleep. Primary snoring is defined according to 
the International Classification of Sleep Disorders (ICSD) as the presence of characteristic 
snoring noises during sleep in the absence of episodes of apnea or hypoventilation (AASM 
2001). 
The severity of OSA has been subdivided into three stages by AHI. Mild OSA is defined 
by AHI 5-15, moderate OSA as 15-30 events per hour, and severe OSA as 30 or more events 
per hour (Iber et al. 2007). 
The upper airway resistance syndrome (UARS) is closely related to OSA. These patients 
have typical symptoms of OSA and they have increased upper airway resistance with 
inspiratory flow limitation, but they do not display any evidence of apneas or hypopneas 
on polysomnography (Guilleminault et al. 1996)).   
2.1.2 Pathogenesis 
The pathophysiology of OSA is not fully understood but the basic mechanism responsible 
for the apnea-hypopnea events during sleep is the repetitive collapse of the upper airway 
due to the possible pathological changes occurring in the upper airway structure and 
alterations in the neural activation of the upper airway musculature. The pharynx is a very 
versatile structure which is responsible for multiple, very diverse functions i.e. speech, 
swallowing and passage of air during breathing. The airway is composed of multiple 
muscles and soft tissue lacking a rigid, bony, support and therefore it is susceptible to 
collapse during sleep. There are other mechanisms believed to be important in the 
pathogenesis of OSA e.g. the synergy of pharyngeal anatomy and diminished ability of the 
upper airway dilator muscles to maintain a patent airway during sleep (Mezzanotte, Tangel 
& White 1992). The function of the upper airway has been described as behaving like a 
Starling resistor  where the upper airway is likened to a hollow tube with a partial 
obstruction at the inlet, corresponding to the nose, and a collapsible section downstream, 
corresponding to the oropharynx. In this model, if there should be negative pressure during 
inspiration, then this can cause greater suction forces in the narrow segment and these may 
contribute in predisposed persons to a collapse of the oropharynx(Smith et al. 1988). During 
sleep, repetitive collapse and obstruction of the upper airway cause increase the  ventilatory 
effort needed to overcome an occluded airway leading to the triggering of a stress reaction 
and eventually to arousal from sleep. After the arousal, when the airway and ventilation 
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are restored, the patient returns to sleep, but the cycle begins again. These recurrent 
arousals cause sleep fragmentation and therefore sleep becomes lighter and more non-
restorative (Kimoff 1996, Berry, Gleeson 1997). Moreover, when the transpharyngeal 
pressure gradient  increases during inspiration and the airflow accelerates in the narrow 
lumen, the pharyngeal tissues begin to vibrate and may collapse and constant repetitive 
eccentric muscle contractions against occluded airway can cause mechanical trauma to the 
upper airway structures. This may lead to adaptive changes in the structure and function of 
the upper airway musculature, thus promoting further deterioration in the upper airways 
(Carrera et al. 1999).  In addition, lung volume is known to influence the caliber of the 
upper airway. Decreased lung volume reduces the pharyngeal cross-sectional area, 
resulting in increased pharyngeal resistance (Bradley et al. 1986, Cormier, Series 1990). 
However, increased lung volume may act both by dilating and stiffening the pharyngeal 
wall (Van de Graaff 1988). 
2.1.3 Prevalence and incidence 
Most of the prevalence studies of OSA are based on the AHI. In the published literature, the 
prevalence of OSA has been estimate to be 4% in males and 2% in females (Young et al. 
1993). On the basis of the average prevalence estimates from studies of cohorts in 
Wisconsin (Young et al. 1993), Pennsylvania (Bixler et al. 2001, Bixler et al. 1998) and Spain 
(Duran et al. 2001) consisting predominantly of white men and women with mean BMI of 
25 to 28, it has been estimated that 20 % adults exhibit signs of at least mild OSA and 7% 
have at least moderate OSA (Young, Peppard & Gottlieb 2002). In Finland, it has been 
estimated that approximately 150,000 patients have OSA, with 57% of them having mild, 
33% moderate and 10% of them suffer from severe disease (Laitinen et al. 2003)(Figure 1). 
Based on the prevalence estimates of previous cohort studies, it is more likely that 
approximately 250,000 to 300,000 have OSA (Young, Peppard & Gottlieb 2002). 
 
 
 
Figure 1. Proportion and severity of obstructive sleep apnea (Laitinen et al. 2003).  
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Although there are numerous studies on the prevalence of OSA, only a few studies have 
provided data on the incidence of OSA. In the Cleveland Family study, the 5 year incidence 
was estimated as 7.5% for moderate OSA and 16% for mild to moderate OSA (Tishler et al. 
2003). 
2.1.4 Progression 
OSA belongs to a group of sleep disordered breathing diseases, it represents a continuum 
of different levels of nocturnal breathing problems. The available epidemiological data 
suggests that OSA has a tendency to worsen over time and the  progression of OSA can 
occur in a relatively short time period with the main determinant of progression being 
weight gain (Berger, Berger & Oksenberg 2009). It seems that there is a linear association in 
OSA patients between weight gain and worsening of OSA, the greater the weight gain, the 
larger is the AHI (Peppard et al. 2000).  
2.1.5 Risk factors 
The main cause of OSA is the upper airway narrowing due to various mechanisms, 
including obesity, impaired nasal breathing, anatomical factors e.g. large tonsils, prominent 
uvula, mandibular micrognathia, medication, male sex and aging. Nonetheless, the most 
important risk factor of OSA is obesity (Young, Skatrud & Peppard 2004) and should the 
value of  BMI exceed 29, this increases the risk for OSA by 10 fold (Pillar, Shehadeh 2008).  
Obesity  
Obesity is considered to be the most important risk factor for OSA (Young, Skatrud & 
Peppard 2004). The majority (60 – 90%) of adult OSA patients are overweight, and in 
patients with BMI>30, the relative risk for OSA is over 10. In addition, in obese patients, the 
prevalence has been reported to be as high as 30-98%. The development or worsening of 
OSA with increasing weight has been demonstrated in several studies (Pillar, Shehadeh 
2008). The mechanisms underlying the association between OSA and obesity are complex 
and most likely multifactorial. The possible mechanisms include reduced pharyngeal 
lumen size due to fatty tissue deposit within the airway or in its lateral walls (Brander, 
Mortimore & Douglas 1999, Martin et al. 1997, Schwab 2005), decreased upper airway 
muscle tone and force due to fatty deposits in the muscle (Carrera et al. 2004, Ryan, Love 
1996), and reduced upper airway size secondary to a mass effect of the large abdomen on 
the chest wall and tracheal traction (Pillar, Shehadeh 2008). In addition, central adiposity 
reduces lung volume (Oppenheimer et al. 2014). Moreover, weight gain has reported to 
increase upper airway collapsibility (Schwartz et al. 1991). There are recent findings 
indicating that in patients with OSA, <50% of the overall response to weight loss may be 
related to reductions in passive mechanical properties and the remaining response to 
concomitant improvements in neuromuscular control of the upper airway (Kirkness et al. 
2008) indicating that there is impaired neuromuscular function in the upper airway 
musculature. 
Age and sex 
It is now recognized that male sex and age are risk factors for OSA. Men have a three- to 
fourfold higher prevalence of OSA than premenopausal women (Young et al. 1993, Duran 
et al. 2001) although, the prevalence of OSA in postmenopausal women approaches that of 
men (Bixler et al. 2001, Redline et al. 1994). Age is also a known risk factor for sleep apnea 
(Oliven et al. 2001, Ware, McBrayer & Scott 2000). The prevalence of OSA increases with 
age reaching its peak at about 55 years of age (Young et al. 1993, Duran et al. 2001, Bixler et 
al. 1998).  
Nasal resistance 
In normal subjects, upper airway resistance is lower during sleep when breathing through 
the nose as opposed to via the mouth. When the nasal airway is almost completely 
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obstructed, nose breathing switches to mouth breathing which is associated with up to 2.5 
times higher total resistance and increased propensity to OSA (Fitzpatrick et al. 2003). In 
addition, the nasal ventilator reflex is known to take part in regulation of the nasal 
resistance during sleep. Activation of nasal receptors during nasal breathing exerts a direct 
positive influence on spontaneous breathing, leading to a higher resting breathing volume 
and frequency (Douglas et al. 1983). The nose accounts for more than 50% of the total 
resistance of the upper airway (FERRIS, MEAD & OPIE 1964).  The recent body of literature 
on the effect of nasal breathing on OSA is somewhat conflicting. A correlation between 
nasal resistance and OSA has been observed in some studies (Lofaso et al. 2000, Li et al. 
2005), whereas in some studies, nasal resistance has not been shown to be related to the 
severity of OSA  (Miljeteig, Hoffstein & Cole 1992) and nasal resistance does not correlate 
with the AHI (Yagi et al. 2009). Furthermore, in different weight groups, the findings on the 
correlation between nasal breathing and OSA have been controversial. Significant 
correlations have been found in obese patients between AHI and nasal resistance (Tagaya et 
al. 2010), while in another study, this relationship was observed only in non-obese patients 
(Virkkula et al. 2003). Nasal steroids have been proven to improve the subjective quality of 
sleep in patients with allergic rhinitis, but are not an effective treatment for adults with 
OSA (Georgalas 2011).  
Anatomical risk factors 
Especially in lean patients, anatomical risk factors play a more significant role in 
predisposing the upper airway to collapse. The possible predisposing factors include large 
tonsils and uvula (Schellenberg, Maislin & Schwab 2000b), low soft palate, retrognathia, 
large tongue and low hyoid bone position (Quera-Salva et al. 1988). Due to all of these 
factors, the airspace of the naso-, and oropharynx decreases and there is a narrowing of the 
upper airways and this increases the risk of OSA in the supine position and a loss of 
neuromuscular compensation at the onset of sleep.  
Cigarette smoking 
A recent review evaluating the interaction between smoking and obstructive sleep apnea 
reported that smoking may increase the severity of OSA by causing alterations in sleep 
architecture, upper airway neuromuscular function, arousal mechanisms and upper airway 
inflammation. On the other hand, there is some evidence to link untreated OSA with 
nicotine addiction (Krishnan, Dixon-Williams & Thornton 2014). At least in terms of nasal 
breathing, smoking has been found to exert adverse effects on the nasal airway. It has been 
associated with increased snoring, nasal obstruction, and pharyngeal soft tissue volume. In 
summary, the combination of current smoking and altered nasal function seems to 
compromise the lower airways and thus, predispose to sleep disordered breathing 
(Virkkula et al. 2007, Virkkula et al. 2005). 
Other risk factors 
Endocrinological abnormalities have been associated with increased OSA risk. For example, 
patients with polycystic ovaries have been found to be 30 times more likely to suffer from 
SDB than controls (Vgontzas et al. 2001). In acromegaly, OSA assessed by 
polysomnography was found in 69% of patients with active disease (Attal, Chanson 2010). 
In addition, an increased prevalence of OSA has been found in patients with 
hypothyroidism (Lin, Tsan & Chen 1992). Alcohol ingestion and sedative medication may 
also be factors contributing to the increased risk for OSA (Scanlan et al. 2000, Rishi et al. 
2010).   
2.1.6 Diagnostic Methods 
Diagnosis of OSA is based on the day and night-time symptoms of the patient, clinical 
findings and always confirmed with a sleep recording. In addition, sleep apnea specific 
questionnaires have been used to quantify the impact on quality of life. Nevertheless, sleep 
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recordings with a portable polysomnography (PSG) is a golden standard method in 
diagnosing OSA. 
Symptoms 
OSA is associated with a huge variety of symptoms in different individuals, which may 
occasionally also cause problems in identifying the disease. Since the majority of the 
symptoms, at least in its early state, are only present during sleep, many subjects with OSA 
may not recognize the symptoms, thus the disease may stay undiagnosed. The most 
common symptoms can be divided into night-time and daytime and are listed below. 
Snoring: Although snoring has a poor diagnostic value in OSA, it is very common among 
OSA patients (Hoffstein, Szalai 1993). Snoring is usually socially disturbing and due to the 
noise of intense snoring, patients may be forced to sleep in separate bedrooms from their 
partners. 
Breathing pauses have been viewed as the characteristic symptom for OSA and considered 
as highly specific for OSA, but many people are unaware of their presence, since their bed 
partner also sleeps during the night, thus not hearing or recognizing them or alternatively 
they sleep alone with no-one to act as a witness. 
Nocturia is a common symptom of OSA, even though most patients and physicians have 
little awareness of the pathophysiological link between this symptom and the sleep 
disorder. A recent study even suggested that nocturia might hold the potential to serve as a 
screening tool for OSA (Romero et al. 2010).  
Daytime sleepiness is the most common feature of OSA. Because of the insidious onset and 
chronicity of OSA, daytime sleepiness may remain unnoticed or its significance may be 
underestimated due to the slow progression of the disease. The patient may not recognize 
the symptom as sleepiness, but may describe the symptoms in other terms, such as fatigue, 
tiredness, and low energy (Chervin 2000). The patient may complain of consistently falling 
asleep while reading, watching television, or even more dangerously, while driving a 
motor vehicle. Even in simple and mild OSA, daytime symptoms may be present. Daytime 
sleepiness is not a very useful clinical symptom with which to try to diagnose OSA (Ward 
Flemons, McNicholas 1997). For example, there are patients with low numbers of apneas 
and hypopneas who complain of significant daytime sleepiness and patients with high 
numbers of apneas and hypopneas who do not exhibit signs of sleepiness (Vgontzas 2008). 
In fact, it has been claimed that the prevalence of OSA without symptoms is higher than the 
prevalence of the disease with symptoms (Young et al. 1993, Duran et al. 2001, Bixler et al. 
2001). This might be interpreted to mean that most OSA patients will exhibit only mild, if 
any, symptoms at all. The severity of OSA and its symptoms usually progress over years 
and increase with weight gain, aging or at the time of menopause. As the disease 
progresses, sleepiness becomes present in all daily activities and can become dangerous 
and disabling. OSA is known to be a possible cause of motor vehicle accidents, resulting in 
a two-fold, perhaps as much as a seven-fold increased risk of being involved in an accident 
(Horstmann et al. 2000). Symptoms of depression and cognitive function impairment have 
also been reported in OSA patients (Engleman, Douglas 2004, Schwartz, Kohler & 
Karatinos 2005). Although all of these symptoms might affect the quality of life, the clinical 
relevance of OSA is mainly due to its strong association with cardiovascular comorbidities. 
Clinical findings 
The most important clinical findings to which particular attention should be paid are the 
presence of obesity and signs of upper airway narrowing. Other features that might point 
to the presence of OSA include increased neck circumference, BMI, waist circumference or 
body fat percentage (Kushida, Efron & Guilleminault 1997), high Mallampati or Friedman 
tongue position score (Friedman et al. 1999), the presence of retrognathia, tonsillar 
hypertrophy, macroglossia, elongated or enlarged uvula, high arched or narrow hard 
palate, nasal abnormalities such as nasal polys, septum deviation, valve abnormalities or 
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turbinate hypertrophy (Lofaso et al. 2000, Young, Finn & Kim 1997, Liistro et al. 2003, 
Zonato et al. 2005, Schellenberg, Maislin & Schwab 2000a). 
Sleep recordings 
The diagnosis of OSA always has to be confirmed at least by overnight cardio-respiratory 
monitoring, where the nasal airflow, respiratory efforts by thoracic and abdominal 
movements, oxygen saturation, heart rate and body position are monitored (Collop et al. 
2007). This measurement can be performed with portable devices at home. A more accurate 
method, which is also the gold standard in OSA diagnostics, is full overnight 
polysomnography recording which needs to be conducted in sleep laboratory facilities 
(Epstein et al. 2009). In addition to overnight cardio-respiratory monitoring, 
polysomnography includes measurements from electroencephalography, eye movements, 
electromyography, electrocardiography, body movements and behavior (Epstein et al. 
2009). Due to the high cost and the need of laboratory facilities, in Finland in patients in 
whom there is a suspicion of  OSA, the diagnosis is often confirmed by un-attended cardio-
respiratory or polysomnographic monitoring. 
2.2 TREATMENT 
Obesity is the most important risk factor for OSA i.e. 60-90% of OSA patients are obese, and 
therefore weight reduction e.g. via lifestyle intervention, forms the cornerstone for the 
treatment of OSA and the prevention of its co-morbidities. The principle medical treatment 
for OSA is CPAP. Other treatment modalities for carefully selected group of patients 
include surgery and oral appliances. 
2.2.1 Lifestyle intervention 
The importance and effectiveness of weight reduction in treating OSA were discovered 
three decades ago (Smith et al. 1985). In the majority of the earlier studies on weight 
reduction in OSA patients, the weight loss was achieved by low and very low calorie diet 
programs, the outcomes have ranged extensively i.e. 3-18% loss of weight and 3-62% 
improvement in AHI (Dixon, Schachter & O'Brien 2005, Kajaste et al. 2004, Kajaste et al. 
1994, Suratt et al. 1992, Kansanen et al. 1998). These previous studies have been reviewed; 
the conclusion was that although weight reduction is important and can facilitate the 
treatment of OSA, it can rarely cure it without being supplemented with classical 
techniques, such as CPAP (Barvaux, Aubert & Rodenstein 2000). Thus, one conclusion 
emerging from these studies has been that while weight loss can reduce the severity of 
OSA, at least in most patients, it cannot be considered as a curative treatment. Thus, 
although weight reduction is recommended in all clinical guidelines, until recently there 
has been a lack of well-executed randomized intervention studies on the effect of weight 
reduction upon OSA. 
In recent randomized controlled studies, it has been demonstrated that lifestyle 
intervention with weight reduction is a feasible and curative for the vast majority of 
overweight OSA patients (Tuomilehto et al. 2009, Foster et al. 2009, Johansson et al. 2009). 
Despite the earlier beliefs that lifestyle intervention with weight reduction could not result 
in curative outcomes and any beneficial effect would not be long-lasting, data from more 
recent studies have tended to indicate that these previous assumptions may not be fully 
justified. In a study conducted in originally severe OSA subjects, it was revealed that almost 
every second patient no longer required CPAP treatment 12 months after the lifestyle 
intervention (Johansson et al. 2011). Weight reduction achieved by lifestyle intervention has 
been demonstrated to exert beneficial, even curative, effects on OSA which have been 
maintained in longer follow-up studies. In a 2 year follow-up study, favorable effects of 
weight reduction sustained at least one year after the discontinuation of the intervention 
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(Tuomilehto et al. 2010). In addition, even though some of the initial weight might have 
returned, a lifestyle intervention with successful weight reduction sustained beneficial 
effects for as long as 5 years after the intervention (Tuomilehto et al. 2014). Furthermore, 
recently it was demonstrated that in the early stages of OSA i.e. mild OSA, a sustained 
weight loss of as little as 5% from the baseline body weight was sufficient to prevent the 
disease from worsening and even cure it when this was investigated in a long-term follow-
up (Tuomilehto et al. 2014).  
2.2.2 Nasal continuous positive airway pressure (CPAP) 
Already for decades, nasal CPAP has been the treatment of choice for OSA since it can 
prevent the upper airway from collapsing during inspiration and expiration, by acting as a 
pneumatic splint to maintain a positive airway pressure (Sullivan et al. 1981). The treatment 
not only alleviates the subjective symptoms, but also achieves improvements in objectively 
measured functions and it can reverse the negative cardiovascular consequences of OSA 
(Bayram et al. 2009, Craig et al. 2009, Cross et al. 2008, Garcia-Rio et al. 2013, Chung et al. 
2011, Ciccone et al. 2011, Alonso-Fernandez et al. 2009). Nasal CPAP therapy is the most 
effective treatment method to treat OSA but the therapy demands good compliance on the 
part of the patient, which often is far from optimal. The compliance has been stated to range 
from 17% to 86%, depending on the method used to measure compliance and the 
compliance criteria (Weaver, Grunstein 2008, Sin et al. 2002). In clinical work with a careful 
evaluation of the treatment modality, the compliance rate is usually 70-80%.  Possible side 
effects for CPAP include dry mouth, nasal blockage, increased amount of awakenings, 
mask pressure and mask leaks (Ulander et al. 2014), which may often be solved by 
providing careful instructions and if needed, some supplemental treatment for the nose and 
the addition of humidifier along with the CPAP device. 
2.2.3 Oral appliances 
Mandibular advancement devices (MAD) protrude the mandible and advance the tongue 
and therefore increase the pharyngeal airway diameter (Ryan et al. 1999). In the last decade, 
oral appliances have proven to be an efficient and safe therapeutic approach in treating 
OSA (Hoffstein 2007). A number of studies have demonstrated the efficacy of MAD use in 
decreasing the AHI, increasing oxyhemoglobin saturation during sleep, reducing blood 
pressure, and improving heart rate variability (Coruzzi et al. 2006, Giannasi et al. 2008, 
Johnston et al. 2002, Otsuka et al. 2006). A recent randomized controlled trial comparing the 
efficacy on MAD and CPAP demonstrated that health outcomes in patients with moderate 
to severe OSA were similar after treatment with CPAP and MAD, mainly due to the better 
compliance with MAD (Phillips et al. 2013). 
2.2.4 Emerging therapies 
New therapies are emerging for OSA e.g. hypoglossal nerve stimulation and genioglossus 
muscle stimulation. The hypoglossal nerve stimulator consists of a stimulator electrode, an 
intrathoracic pressure sensor and a programmable pulse generating system. Delivery of the 
stimulus is synchronized with the patient’s respiratory pattern, allowing the stimulation to 
be triggered just prior the inspiration. Electrical stimulus is then considered to restore 
pharyngeal patency by activating the dilator muscles (Schwartz et al. 2001). The device has 
been demonstrated to increase respiratory flow without arousal from sleep. Two of the 
recent studies have demonstrated clinically meaningful reductions in AHI and 
improvements in QoL (Kezirian et al. 2014, Strollo et al. 2014)  On other hand, at present, 
the treatment is expensive and previous studies have also stated that the efficacy of the 
stimulator device is limited, because residual disease still persists in most patients and since 
there are some safety concerns about the method, it will require more investigation before it 
becomes a routine therapy (Eastwood et al. 2011, Mwenge et al. 2013, Van de Heyning et al. 
2012). 
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In transcutaneous genioglossus muscle stimulation, bilateral electrode patches are placed 
submentally and cables from the patches are connected to the stimulation device. The 
electrical stimulus to genioglossus muscle evokes a measurable contraction of the tongue 
and pharyngeal muscles resulting in a reduced ventilatory load. The effectiveness of this 
novel method for the treatment OSA still needs to be clarified (Steier et al. 2011). 
2.2.5 Surgical treatment 
The aim of surgical treatment is to achieve an increase in the diameter of the upper airway 
by removing the obstructed site and therefore decreasing airway resistance. Surgical 
treatment is seldom used in OSA but in very rare cases where the anatomical site of the 
obstruction has been identified and other possible causes eliminated, then surgical 
treatment can be beneficial. Especially in children, OSA is mainly treated with 
adenotonsillectomy, where hypertrophy of adenotonsillar tissue is present. In these cases, 
adenotonsillectomy is considered as a curative strategy. The sites of the surgical interest are 
nose, oropharynx, hypopharynx, maxillofacial structure and trachea. In addition, bariatric 
surgery has its own distinct place in weight reduction surgery (Kotecha, Hall 2014). 
Nasal surgery 
Nasal surgery has its benefits not as a curative treatment for OSA but as an adjunctive 
treatment to improve the efficacy of CPAP (Li et al. 2008). Even though nasal surgery does 
display some benefits in the improvement of QoL measures, it seldom offers any 
improvements in terms of AHI (Verse, Maurer & Pirsig 2002). 
Tonsillectomy and uvulopalatopharyngoplasty (UPPP) 
Tonsillectomy, in two case series, achieved an over 50% reduction in postoperative AHI in 
patients with mild, moderate and severe OSA and with grade III and IV tonsils (Verse et al. 
2000, Tan et al. 2013). Uvulopalatopharyngoplasty is intended to enlarge the retropalatal 
diameter. The overall success rate in mild to severe OSA is reported to be approximately 
40% but it is accompanied by comparatively large morbidity and may interfere with the 
later CPAP treatment (Browaldh et al. 2013). Thus, nowadays UPPP is very seldom 
undertaken but uvulopharyngolplasty which includes tonsillectomy, uvuloplasty and 
minor plasty of posterior palatinal arches, is occasionally used to replace UPPP. 
Hypopharyngeal procedures 
Tongue base surgery with radiofrequency thermoablation has been claimed to exert some 
beneficial effects which last as long as 24 months after the procedure (Farrar et al. 2008). A 
case series of midline glossectomy with fifty OSA patients demonstrated an improvement 
in postoperative AHI values in 56% of the patients. The success rate depended on the 
tongue position (Suh 2013).  
Maxillomandibular advancement 
In selected cases, especially in patients with craniofacial deformities, maxillomandibular 
advancement can achieve an expansion of the upper airway at multiple levels and this is 
accompanied by positive long term follow up results (Holty, Guilleminault 2010).  
Bariatric surgery 
In some morbidly obese patients with OSA, bariatric surgery can represent an efficient 
treatment although it rarely can be considered as curable (Lettieri, Eliasson & Greenburg 
2008, Haines et al. 2007) and there is a report that it is not superior to more conventional 
weight loss therapies (Dixon et al. 2012). 
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2.3 CO-MORBIDITIES 
2.3.1 Mortality 
In several studies, the association between moderate to severe OSA and cardiovascular 
mortality has been demonstrated, although no significant increase has been clearly shown 
to be associated with mild OSA (Nieto et al. 2000, Somers et al. 2008, Yaggi et al. 2005, 
Shahar et al. 2001, Gottlieb et al. 2010). In a recent study of Finnish OSA subjects, the overall 
mortality was 26.4 % in moderate to severe OSA cases while in patients without OSA, it 
was  9.7 %. It was estimated  that the  hazard ratio for cardiovascular mortality was 4.04 in 
the moderate to severe OSA cases and 1.87 in subjects with mild OSA (Muraja-Murro et al. 
2013b). On the other hand, in a recent meta-analysis of the studies investigating the 
relationship of severe OSA and all-cause mortality, the overall pooled RR in relation to 
severe OSA was 1.92 (Wang et al. 2013) varying from 1.46 (Punjabi et al. 2009) to 3.80 
(Young et al. 2008). 
2.3.2 Cardiovascular co-morbidities 
Several epidemiological studies have highlighted the strong link between OSA and 
cardiovascular diseases such as hypertension, coronary arterial disease, stroke and heart 
failure (Nieto et al. 2000, Peppard et al. 2000, Shamsuzzaman, Gersh & Somers 2003). Since 
OSA is a treatable disease and prevention and treatment of OSA could reduce the incidence 
of cardiovascular events, a clearer understanding of the relationship between OSA and the 
risk of cardiovascular co-morbidities could have an important impact on public health and 
the severity of the possible complications of the disease (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Consequences of OSA and the possible mechanisms of the evolution of cardiovascular 
co-morbidities. Adapted from (Durgan, Bryan 2012). 
Hypertension 
There is strong evidence supported by large epidemiological studies that OSA is an 
independent risk factor for hypertension and furthermore the majority of the OSA 
population has been reported to suffer from hypertension (Nieto et al. 2000, Bixler et al. 
2001, Peppard et al. 2000, Lavie 2003). Patients with mild to moderate OSA had an up to 
three fold risk of developing new hypertension during a four year follow-up (Peppard et al. 
2000). Moreover the association between OSA and the presence of hypertension has been 
found to be dose related (Nieto et al. 2000, Peppard et al. 2000, Young, Finn & Kim 1997, 
Lavie 2003, Grote, Hedner & Peter 2001). Importantly, drug resistant hypertension is linked 
with OSA (Somers et al. 2008).  On the other hand, BMI and age are the major risk factors 
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for both OSA and hypertension (Bixler et al. 1998, Young, Skatrud & Peppard 2004, Hedner
et al. 2006)  and even mild OSA seems to add to the risk of hypertension (Young et al. 1997).
There are several studies suggesting that CPAP, oral appliances and weight loss can
achieve a significant reduction in blood pressure (Andren, Sjoquist & Tegelberg 2009,
Aucott et al. 2005, Martinez-Garcia et al. 2013) and furthermore, these interventions
naturally also improve OSA symptoms and parameters.
Coronary artery disease (CAD)
The underlying mechanisms leading to the formation and progression of atherosclerotic
plaques in the arterial wall involve multiple factors such as oxidative stress, endothelial
dysfunction, and inflammatory and immunologic factors. In OSA patients, the oxidative
stress caused by repeated hypoxia and oxygenation during sleep, can ultimately cause
vascular damage. Recent studies have increasingly addressed the role of OSA as an
independent  risk  factor  of  CAD.  In  OSA patients  without  any other  risk  factors  for  CAD,
signs of atherosclerosis have been found in the large arteries. Because OSA and CAD share
the same risk factors, it is difficult to prove that there is causal relationship between OSA
and CAD. However OSA has been independently associated with subclinical coronary
atherosclerosis, and also OSA patients have a higher prevalence of non-calcified obstructive
atherosclerotic plaques. An observation from a study of OSA patients who manifested signs
of early atherosclerosis that were responsive to CPAP treatment, supports the theory of
OSA being an independent risk factor for atherosclerosis. Multiple longitudinal studies
have reported that untreated OSA patients are at risk of developing CAD, when adjusted
for other risk factors. In the community-based Sleep Heart Health Study, an association was
detected between OSA and incidents of CAD in severe OSA patients. In contrast, recent
observational studies have found an association between OSA, acute myocardial infarction,
incident coronary events or cardiac death after adjusting for other known risk factors (De
Torres-Alba et al 2013).
Stroke
Several studies have recently pointed out that untreated OSA is an independent risk factor
for stroke. One observational cohort study stated that OSA was associated with a combined
endpoint of stroke and death, with an adjusted hazard ratio of 1.97 and that this risk was
independent of other factors such as hypertension (Yaggi et al. 2005). Similarly, elderly
patients with severe OSA were found to have an increased risk of stroke. This relationship
was independent of other confounders such as blood pressure and hyperlipidemia (Munoz
et al. 2006). The Sleep Heart Health study demonstrated that OSA was 30 % more common
among those patients who developed ischemic stroke. The study also revealed a strong
adjusted association between ischemic stroke and OSA in community-dwelling men with
mild to moderate OSA and with moderate to severe OSA in women (Redline et al. 2010).
The cross-sectional analysis of the results of the Wisconsin Sleep Cohort Study
demonstrated that moderate to severe sleep apnea was associated with an increased risk of
stroke after adjustment for confounders (Arzt et al. 2005). In addition, a recent meta-
analysis of five studies also concluded that OSA was associated with stroke incident (Loke
et al. 2012).
Heart failure
OSA may play a role in the pathogenesis of cardiac failure through mechanical, adrenergic
and vascular mechanisms (Bradley, Floras 2003). In a large community study, the presence
of OSA increased the likelihood of suffering heart failure with a 2.38 odds ratio, this being
independent of other known risk factors (Shahar et al. 2001). In a study investigating male
heart failure patients, at least mild OSA was found in 68% of the patients and moderate to
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severe OSA in 49% of the patients (Javaheri 2006). Similar results showing a high 
prevalence of OSA among heart failure patients have been demonstrated in several studies 
(Bitter et al. 2009, Ferreira et al. 2010, Herrscher et al. 2011, Oldenburg et al. 2007, Zhao et al. 
2007). In addition, treatment of OSA has exerted beneficial effects on survival of heart 
failure patients (Javaheri et al. 2011). 
Atrial fibrillation 
It has been claimed to be an association between OSA and nocturnal disturbances of cardiac 
rhythm (Shamsuzzaman, Gersh & Somers 2003). Individuals with OSA experienced a 4-fold 
increase in their adjusted risk for atrial fibrillation in a cross-sectional component of the 
Sleep Heart Health Study (Mehra et al. 2006)]. OSA was found in 49% of the patients who 
were referred for electrical cardioversion for atrial fibrillation (Gami et al. 2004)]. In 
addition, after cardioversion there was a significantly higher recurrence of atrial fibrillation 
in those individuals with OSA (Kanagala et al. 2003). 
Pulmonary hypertension 
Due to the variations in methods for defining pulmonary hypertension, it has proved rather 
difficult to study the association between OSA and pulmonary hypertension. In some 
recent studies, the estimated prevalence of pulmonary hypertension among OSA patients 
ranged from 17% up to 53% (Atwood et al. 2004) although there is one study where the 
prevalence was claimed to be as low as 10% (Javaheri, Javaheri & Javaheri 2013). Treatment 
of OSA in patients with pulmonary hypertension has resulted in a modest hemodynamic 
improvement. 
2.4 PATHOGENESIS OF CARDIOVASCULAR CO-MORBIDITIES IN OSA 
The pathogenesis of cardiovascular complications in OSA is most likely related to sleep 
fragmentation and hypoxia. Although not completely understood, the exact underlying 
pathways are considered as being multifactorial. The proposed mechanisms predisposing 
to cardiovascular disease include sympathetic activation, systemic inflammation, oxidative 
stress and endothelial dysfunction (Shamsuzzaman, Gersh & Somers 2003, Lavie 2003, 
Atkeson, Jelic 2008, Jurado-Gamez et al. 2011). Recent epidemiological studies have 
revealed OSA to be an important risk factor for increased mortality, particularly due to 
coronary artery disease, and only in those patients with severe OSA (Punjabi et al. 2009). 
During nocturnal recurrent episodes of obstructive apnea and hypopnea, the inspiratory 
effort against an occluded airway leads to negative pressure in the pleural space. Should 
the apnea or hypopnea persist, hypoxemia and hypercapnia become more profound, 
leading to pulmonary vasoconstriction and the development of transient pulmonary 
hypertension (Adegunsoye, Ramachandran 2012). Simultaneously there is a stimulation of 
the sympathetic nervous system, triggering systemic vasoconstriction and arterial 
hypertension (Leuenberger et al. 1995). In addition, this phenomenon of hypoxia and 
hypercapnia followed by subsequent reoxygenation is repeated several times during the 
same night, causing changes in reperfusion, production of free radicals, endothelial 
dysfunction and oxidative stress. These changes are considered as major contributors to the 
cardiovascular consequences in OSA (Somers et al. 2008, Shamsuzzaman, Gersh & Somers 
2003, Lavie 2003, Atkeson, Jelic 2008). 
2.4.1 Endothelial dysfunction 
The endothelium of the vascular wall is responsible for maintaining the balance of 
vasoconstriction and vasodilatation. Damage in the arterial wall leads to endothelial 
dysfunction (Shamsuzzaman, Gersh & Somers 2003). In cardiovascular disease, endothelial 
dysfunction is one of the early markers of atherosclerosis and its presence associates with 
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increased cardiovascular adverse events (Vita, Keaney 2002). A strong association has been 
detected between OSA and endothelial dysfunction (Kato et al. 2000, Forgione, Leopold & 
Loscalzo 2000, Feng, Zhang & Chen 2011). Vascular endothelial dysfunction represents the 
loss of normal homeostatic functions in the blood vessels, being characterized by reduced 
vasodilatation and enhanced vasoconstrictory effects and chronic prothrombotic and 
inflammatory activity (Davignon, Ganz 2004). Endothelial dysfunction is considered as the 
first marker of the initiation of atherosclerosis also in OSA subjects (Foster, Poulin & Hanly 
2007). Patients with moderate to severe OSA have been found to display impaired 
endothelial function and thus, to be at an increased risk of suffering cardiovascular diseases 
(Priou et al. 2010, Bayram et al. 2009, Kato et al. 2000). Several mechanisms have been 
proposed to explain the association between OSA and endothelial dysfunction. There is 
evidence also to suggest that OSA may independently impair endothelial function by 
reducing nitric oxide bioavailability and altering the regulation of endothelial vasomotor 
tone and cell repair capacity, while promoting vascular inflammation and oxidative stress. 
The mechanisms thought to be involved in the impaired endothelial function include 
repetitive hypoxia, sleep fragmentation and deprivation. It seems that there are some 
controversies related to the association between mild OSA and endothelial dysfunction. In 
some studies, preserved endothelial function has been observed in mild OSA cases 
(Yoshihisa et al. 2010, Chung et al. 2007) however, there have also been reports of 
endothelial dysfunction in patients with mild SDB (Nieto et al. 2000, Vita, Keaney 2002, 
Duchna et al. 2006, Faulx et al. 2004, Oflaz et al. 2006). In moderate to severe OSA, 
endothelial dysfunction has been found to be more evident (Bayram et al. 2009, Kato et al. 
2000, Oflaz et al. 2006, Nguyen et al. 2010, Patt et al. 2010, Ip et al. 2004, Imadojemu et al. 
2002). Impaired FMD has previously been associated with metabolical parameters related 
to impaired glucose and lipid metabolism, at least in studies conducted in older OSA 
patients (Nieto et al. 2004), patients with metabolic syndrome (Angelico et al. 2011) and in 
patients with hyperglycaemia (Caballero et al. 1999). It has been shown that endothelial 
dysfunction also develops in patients with other cardiovascular risk factors such as 
hypertension, diabetes mellitus, hyperlipidemia, obesity, and in smokers even before the 
signs of atherosclerosis develop. In addition, endothelial function can be restored by 
treating OSA or other risk factors (Clarkson et al. 1996, Gokce et al. 2001, Tounian et al. 
2001). 
2.4.2 Oxidative stress 
Repetitive hypoxemia and reoxygenation may be one of the main factors in the triggering 
of oxidative stress mechanisms (Suzuki et al. 2006, Schulz et al. 2000, Prabhakar 2002). Some 
studies have reported increased levels biomarkers associated with oxidative stress in OSA 
patients (Lavie 2003) although these changes have not been confirmed in other studies 
(Svatikova et al. 2005). Microarray measures of gene transcription in OSA subjects before 
and after sleep have pointed to the activation of several mechanisms that may attempt to 
modulate or adapt the increase in the levels of reactive oxygen species developing in 
response to overnight hypoxemia (Hoffmann et al. 2007). 
2.4.3 Inflammation 
Systemic inflammation is considered to be one of the most important pathophysiological 
mechanisms explaining the progression of atherosclerosis from the appearance of foam cell 
to plaque formation and eventually to plaque rupture and thrombosis (Libby 2002). In OSA 
it is suggested that the oxidative stress caused by intermittent hypoxia will eventually lead 
to the synthesis of inflammatory cytokines thus promoting the expression of adhesion 
molecules especially in the vascular endothelium (Lavie, Lavie 2009). The atherosclerotic 
plaque is a collection of inflammatory cells and their cytocine products which play an 
essential role in cardiovascular disease (Hansson, Libby 2006). 
It has been postulated that OSA activates both the proinflammatory system and 
inflammary system (Sahlman et al. 2010). However it still remains uncertain whether OSA 
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itself modulates the circulating inflammatory biomarkers or do other factors such as the 
repetitive microarousals, overweight, metabolic syndrome or prediabetes, which are often 
encountered in OSA patients, alter the inflammatory system (Salmenniemi et al. 2004, 
Donath 2011). 
2.4.4 Sympathetic activation and baroreflex sensitivity 
Sympathetic activation appears to be one of the key factors responsible for the hypertension 
present in patients with OSA (Somers et al. 1995, Noda et al. 1993, Cortelli et al. 1994). 
Chemoreceptor stimulation induced by intermittent hypoxemia, repeated arousals and 
impairment of baroreflex control may play a role in the triggering of sympathetic activation 
in OSA (Carlson et al. 1996, Sforza et al. 1994, Ziegler et al. 1995). The impairment of the 
baroreceptor reflex sensitivity (BRS) has frequently and independently been observed in 
OSA patients (Carlson et al. 1996, Parati et al. 1997, Cooper et al. 2005, Grassi et al. 2005). In 
addition, impaired BRS is a marker of autonomic dysfunction in several major diseases 
such as diabetes, chronic heart failure and coronary artery disease (Frattola et al. 1997, La 
Rovere et al. 1998, Mortara et al. 1997). Depressed BRS has been found to be a significant 
predictor of arrhythmic death in patients recovering from acute myocardial infarction (La 
Rovere et al. 1998, La Rovere et al. 2001, La Rovere, Schwartz 1997, Farrell et al. 1992). 
Independent of obesity, BRS is known to be impaired in moderate or severe OSA, but there 
is no agreement about whether BRS becomes disturbed already in mild OSA (Ryan et al. 
2007). Nonetheless, it is generally believed that sympathetic activation is one of the key 
mechanisms linking sleep apnea to cardiovascular disease (Narkiewicz et al. 1998b, 
Narkiewicz et al. 1999, Imadojemu et al. 2007).  
2.4.5 Increased blood coagulation 
Increased platelet aggregation and enhanced coagulability are present in patients with OSA 
(Bokinsky et al. 1995, von Kanel, Dimsdale 2003). In addition, the levels of coagulation 
factors are elevated in OSA patients (Wessendorf et al. 2000), along with the levels of 
plasma fibrinogen and plasminogen activator (Rangemark et al. 1995). Furthermore, it has 
been reported that treatment with CPAP is associated with a reduction in both fibrinogen 
levels and the activity of plasminogen activator, suggesting that OSA may be causally 
associated with increased coagulability (von Kanel et al. 2006, Chin et al. 1996). 
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3 Aims of the Study 
The aims of the present study were 
 
1. To evaluate whether overweight patients with mild OSA displayed endothelial 
dysfunction, and to assess the effect of a 1-year lifestyle intervention with a very low 
calorie diet (VLCD) on endothelial function. (Study I). 
2. To investigate whether an impairment of BRS could be detected in overweight 
patients with mild OSA. (Study II). 
3. To examine whether impaired nasal airflow might explain the missing effect of 
weight reduction in OSA (Study III). 
4. To determine whether cigarette smoking could exert a negative impact in the 
improvement of OSA. (Study III) 
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4 Material and Methods 
4.1 SUBJECTS 
This randomized study was originally conducted to determine the effects of changes in 
lifestyle with weight reduction program designed to prevent the progression of OSA and 
cardiovascular risk factors in the most prevalent subgroup of OSA i.e. overweight patients 
with mild OSA. The study protocol was approved by the Research Ethics Committee of the 
Hospital District of Northern Savo, Kuopio, Finland. The recruitment started in October 
2004 and ended in December 2006. All patients who were referred to the Department of 
Otorhinolaryngology of Kuopio University Hospital due to a suspicion of sleep disordered 
breathing between 2004 and 2006 were assessed. Patients were assigned to undergo 
diagnostic nocturnal cardiorespiratory monitoring. Weight and height were measured, and 
the upper airway pathologies of the patients were evaluated. The inclusion criteria for the 
initial trial were 1) age 18–65 y, 2) body mass index (BMI; in kg/m2) 28–40, and 3) an apnea-
hypopnea index (AHI) of 5 to 15 events/h. We also excluded patients due to active 
treatment of OSA of any kind, as well as pregnant women and those with chronic kidney, 
thyroid or liver disease. The control group consisted of non-OSA snorers who fulfilled the 
above mentioned inclusion criteria 1 and 2 as in the OSA group, but had AHI <5.  
4.2 STUDY DESIGN 
4.2.1 Baseline cross-sectional study on cardiovascular risk factors (Studies I and II) 
The baseline cross-sectional study comprised of two analyses; cross-sectional comparison of 
1) endothelial function and 2) BRS between patients with mild OSA (AHI 5-15/h) and non-
OSA snorers (AHI <5). At baseline, the study population consisted of 83 overweight 
patients with mild OSA and 46 weight-matched non-OSA subjects. 
4.2.2 Follow-up study on endothelial dysfunction (Study I) 
The follow-up study represented a 1-year randomized, controlled trial (RCT) on the effect 
of weight loss on the endothelial function in patients with mild OSA (Fig. 1).  At baseline, 
the study population consisted of 83 overweight patients with mild OSA. The subjects were 
randomized into two study groups by a study nurse according to a previously generated 
randomization plan. The study nurse did not participate in the intervention section of the 
study, nor did the study nutritionist see the patients before the first group session for the 
intervention group. No stratification was used in the randomization of the participants into 
the two groups (Tuomilehto et al. 2009). In the RCT, the patients were allocated into either 
an intensive lifestyle intervention group or a control group. The intervention group 
received a 1-year lifestyle intervention with an initial weight reduction program with 12 
weeks on a very low calorie diet (VLCD). The control group were provided with a single 
general dietary and an exercise counselling session. The main objective of the study was to 
assess the endothelial function in patients with mild OSA and the effect of weight loss on 
endothelial function. The working hypothesis was that already in mild OSA, endothelial 
function could be impaired and a successful weight reduction with lifestyle intervention 
would result in an improvement during a 12-month follow-up.  
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4.2.3 Follow up study on factors possibly preventing the beneficial effect of weight 
reduction in (Study III) 
This study was a 1-year follow-up study.  Fifty-two overweight adult patients with mild 
OSA were recruited and underwent additional rhinometric measurement along with the 
cardiorespiratory recording. Based on previous studies of lifestyle intervention, it was 
decided that the lifestyle intervention period of 12 months would be considered successful 
if the patients achieved a minimum of 5% weight reduction (Lindstrom et al. 2008, 
Uusitupa et al. 2009). The patients who succeeded in achieving a 5% weight loss were 
further divided in two groups based on the value of the AHI at the 12-month follow-up. 
The subjects, who were able to diminish their AHI under the cut point value of 5 events/h, 
were considered to be objectively cured from OSA (non-OSA group). Patients in the other 
group had AHI ≥ 5 events/h (OSA group). For further analysis, the patients were also 
divided into smokers and non-smokers. The aim of the study was to determine whether 
impaired nasal breathing and cigarette smoking could prevent the beneficial effects of 
weight reduction achieved by lifestyle intervention on OSA 
4.4 METHODS 
4.4.1 Anthropometric data 
BMI was determined as weight (kg) divided by the square of height (m2).  Blood pressure 
was measured on the right arm with the subject in the sitting position, and the 
measurement was repeated three times, after 10 minutes of rest, using a standard 
sphygmomanometer. The mean value of the measurements was used as the result. At the 
study site, a trained nurse measured height, weight, waist circumferences and blood 
pressure at the baseline and at the 1-year visit. The total body fat percentage was measured 
with an InBody 3.0 bioimpedance device (Biospace; Seoul, Korea). The multifrequency 
bioimpedance method provides detailed information on fat mass, and also gives estimates 
of lean mass, total body water and fat distribution within the whole body and segmental 
lengths. When compared with the dual energy X-ray absorptiometry method, InBody 
analysis has been shown to provide a good assessment of fat mass in healthy subjects 
(Salmi 2003). 
4.4.2 Cardiorespiratory monitoring 
Nocturnal 6-channel unattended single night cardio-respiratory monitoring by Embletta® 
(Embla, Broomfield, CO, U.S.A.) at home was conducted in accordance with accepted 
guidelines for diagnosing OSA (AASM 1999). Nasal flow by nasal flow detector, thoracic 
and abdominal movements by two piezoelectric belts, oxygen saturation and heart rate by 
finger pulse oximeter and body position were monitored. A trained physician then 
evaluated the recordings in a blinded manner. Apnea was defined as a cessation (≥ 90 %) of 
airflow of ≥ 10 seconds. Hypopnea was defined as a reduction (≥ 30 %) of airflow of ≥ 10 
seconds with oxygen desaturation ≥ 4 %. The apnea-hypopnea index was defined as the 
number of apneas and hypopneas per hour, and mild OSA was defined as AHI 5-15 
events/h. (Iber et al. 2007, Collop et al. 2007). The following parameters were also assessed; 
arterial oxygen saturation, time and percentage with arterial oxygen saturation below 90%, 
and heart rate. The cardiorespiratory recordings were conducted at the baseline and at the 
1-year visit. All the biochemical measurements were performed both at baseline and at the 
1-year visit after a 12-hour fasting period. In the present study, the results were based on 
sleep recordings from a single night. In routine practice, repeated recordings are extremely 
demanding, and the findings of single-night recordings have been found to be reliable in 
most patients (Fietze et al. 2004). 
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4.4.3 Biochemical measurements 
Biochemical measurements were performed both at baseline and at the 1-year visit in the 
Laboratory of Clinical Chemistry in Kuopio University Hospital. From fresh serum samples 
cholesterol, high-density lipoprotein, triglycerides, alanine aminotransferase and glucose  
were analyzed by using an automated analyzer system (Konelab 60 analyzer; Thermo 
Fisher Scientific, Waltham, MA), and insulin was measured with a fluoroimmunoassay 
technique (Wallac; PerkinElmer, Waltham, MA). 
4.4.4 Ultrasound studies (FMD) 
Ultrasound studies were performed using Sequoia 512 ultrasound mainframes (Acuson, 
Mountain View, California). To assess brachial flow mediated dilatation (FMD), the left 
brachial artery diameter was measured both at rest and after reactive hyperaemia. 
Increased flow was induced by inflation of a pneumatic tourniquet placed around the 
forearm to a pressure of 250 mm Hg for 4.5 minutes, followed by release. Three 
measurements of arterial diameter were performed at end diastole at a fixed distance from 
an anatomic marker at rest and at 20, 40, 60, 80 and 100 seconds after cuff release. The 
brachial artery diameter in scans after reactive hyperaemia was expressed both as the 
change in absolute diameter (FMD) and as the percentage change relative to the resting 
scan (FMD%). After a 10 min wash-out period, nitrate (glyceryl trinitrate spray 0.4 mg/dose, 
Nitrolingual-Pocket) was administered per os. Nitrate-related vasodilatation (NTG%) was 
assessed from the maximally dilated vessel diameter 3–5 min after nitrate administration 
relative to the vessel diameter at rest before nitrate administration. 
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Figure 3. Assessment of brachial artery flow mediated vasodilation (a). Brachial artery at 
baseline (b). Brachial artery after shear stress (c). FMD%= ((4.16- 3.76)/3.76) x100=10.6 
%≈11%. Adapted from (Saarelainen 2012). 
4.4.5 Assessment of baroreflex sensitivity 
Five minutes after the controlled breathing test, BRS was evaluated, following with a 
modification of the method originally described by Smyth et al. (Smyth, Sleight & Pickering 
1969). In brief, a bolus injection of 150 μg phenylephrine was administered into the 
antecubital vein to produce a rapid increase in blood pressure and a concomitant reduction 
in heart rate (increase of R-R interval) (Fig 4) Beat-to-beat values of R-R intervals (RRIs) 
were plotted against the systolic arterial pressure (SAP) values of the preceding cardiac 
cycle [i.e., RRI(i) vs. SAP(i - 1)] during the period in which blood pressure  increased after 
phenylephrine administration. A linear regression analysis between RRI(i) and SAP(i-1) 
was performed and expressed as follows: RRI(i) (ms  (mmHg), where i is one individual 
cardiac cycle and i -1 is the cardiac beat preceding the i beat (Fig 4). The slope of the 
regression line (b) represents BRS, and a and b are a constant and coefficient, respectively, 
that represent the linear regression (first-order equation). Only tests with correlation 
coefficients of r > 0.80 or that were statistically significant (P < 0.05) were accepted. The 
phenylephrine test was repeated at 10-min intervals up to five times to gather three 
acceptable measurements. The average of the three measurements was used in the 
assessment of BRS. In two cases, it was not possible to obtain any acceptable BRS values 
because of technical problems or ectopic beats. Furthermore, BRS proportional to age and 
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sex related reference values was calculated as percentage (Laitinen et al. 1998). The 
coefficient of variation and the correlation coefficient of two measurements that were 
performed at 3-mo intervals were 7.4% and 0.903, respectively (Hartikainen et al. 1995). 
 
 
 
 
Figure 4. The BRS slope method describes the relationship between the change in the RR 
interval in response to the change of systolic blood pressure of the preceding cardiac cycle. The 
slope of regression line corresponds to arterial baroreflex sensitivity of 8.67 ms/mmHg with an 
acceptable correlation coefficient of 0.95. RRI= RR interval; SAP=systolic arterial pressure. 
4.4.6 Lifestyle intervention 
On the first visit, the patients were informed about the general health risks associated with 
OSA and obesity and provided with information about harmful lifestyle habits, such as 
smoking and alcohol drinking. Both the doctor and the nurse stressed the importance of 
diet and exercise to the control group, but no specific, individualized programs were 
offered to the subjects in the control group. 
The 12 month intensive lifestyle intervention consisted of 14 visits with the study 
nutritionist. To estimate their nutrient intake, patients in the intervention group were asked 
to keep a 3-day food diary at baseline. After screening, participants in the intervention 
group started to adhere to a group-based very low calorie diet (VLCD) of 600–800 kcal/day 
(Nutrilett® [Nycomed Pharma, Oslo, Norway], Modifast® [Novartis, Basel, Switzerland], 
Nutrifast® [Leiras, Helsinki, Finland], or Naturdiet® [Vitamex, Norrköping, Sweden]) for 
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12 weeks. At the beginning of the intervention, an individual goal was set for weight loss. 
During the VLCD period, follow-up visits were arranged every second week and the 
sessions were supervised by the nutritionist. Compliance with the program and 
supervision for any possible adverse events were monitored by individual interviews at 
each visit by the nutritionist. Anthropometrics were measured at every visit and the 
patients were asked about any lifestyle changes he or she had made.  In addition to VLCD 
products, the patients were allowed to consume calorie-free drinks and vegetables in 
accordance with the outpatient clinic's weight reduction program. The clinical nutritionist 
provided dietary and lifestyle counseling at each visit, with the emphasis placed on diet, 
exercise, and modification of lifestyle in general. After the VLCD program, the patients 
were advised to reduce fat to no more than 30% of total energy by increasing their intake of 
fruits, vegetables, poultry, fish, and lean meat, and by limiting consumption of dairy fats, 
fatty meat, sweets, pastries, and desserts. The subjects were recommended to increase their 
daily physical activity, and endurance exercise (such as walking, skiing, jogging, or 
swimming) was also recommended. After the VLCD, a physiotherapist supervised two 
group meetings which focused on circuit-type resistance exercise to improve functional 
capacity. During the intervention period, the rate of participation in these sessions varied 
from 70 to 80%. 
Any possible adverse events related to the weight reduction program were assessed by 
the nutritionist at the visits which took place at two week intervals. All the results of the 
laboratory tests, blood pressure measurements, and electrocardiograms were checked by 
study physicians. It was decided that if any abnormal test results endangering the health of 
the study participants were observed, then participants would be informed and referred for 
appropriate medical care. 
4.4.7 Rhinomanometric measurements 
Rhinomanometry was performed at baseline, and at 12-month follow-up visit. A NR6-
rhinomanometer (GM Instruments Ltd, Glasgow, UK) was used to conduct the 
rhinomanometric recordings, whereby total inspiratory nasal resistance was recorded at a 
radius of 200 Pascal.(Broms, Jonson & Lamm 1982) After a 15 minute period for 
acclimatization, , four recordings were made: first in the seated position, next in the supine 
position after lying down for 5 minutes, the third was conducted at 10 minutes after nasal 
decongestion in the supine position and the fourth measurement after 5 minutes in the 
seated position. Nasal decongestion was achieved by swabbing the mucosa of the inferior 
and middle nasal turbinates with a solution containing 20µg/ml adrenaline and 40mg/ml 
lidocaine. 
4.4.8 Symptoms and quality of life measurements  
Epworth Sleepiness Scale (ESS)(Johns 1991), Snore Outcome Survey (SOS) (Gliklich, Wang 
2002) and Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini RQLQ) (Juniper et 
al. 2000) scores were obtained at the baseline and at 12 months. The ESS is an eight item 
score evaluating daytime somnolence in eight specific situations. Total ESS score can vary 
from 0 (best) to 24 (worst) and a total score exceeding 10 points is considered to be 
abnormal. The SOS is a disease specific outcome score that contains eight items evaluating 
the duration, severity, frequency and consequences associated with SDB, especially 
snoring. Scores on the SOS are normalized on a scale ranging from 0 (worst) to 100 (best). 
The MiniRQLQ has 14 items in five domains; activity limitations, practical problems, nasal 
symptoms, eye symptoms and other symptoms. In the questionnaire, the subjects are asked 
to consider how they had experienced the previous week and to respond to each question 
on a seven-point scale (0 = no impairment, 6 = maximum impairment). In the present study, 
eye symptoms were not assessed leaving the questionnaire with 9 items. Therefore, the 
range of total miniRQLQ score can vary from 0 (no impairment) to 54 (maximum 
impairment). Patient’s lifestyle habits, such as smoking were also recorded. 
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4.4.9 Clinical examination 
At all the visits, the clinical assessments for all patients were done by an 
otorhinolaryngologist. A complete otorhinolarynoglogic status was obtained, including 
examination of pharynx and larynx in Müller’s maneuver with a fiber-endoscope. 
Moreover, special attention was paid to possible obstructing sites in the upper airway i.e. 
enlarged tonsils, retrognathia and Mallampati class, nasal polyps and nasal congestion. 
Moreover, patients in study III were evaluated more precisely in terms of nasal pathologies. 
In these patients, nasal polyposis, septal deviation and nasal congestion were evaluated 
using a three point scale in each variable (0= no polyps/deviation/congestion, 1= minor 
obstruction caused by polyps/deviation/congestion 2= nasal cavity entirely obstructed by 
polyps/deviation/congestion). Based on these individually measured nasal factors, the total 
nasal airway obstruction was evaluated on a seven-point scale (0= no obstruction, 6= total 
obstruction)   
4.4.10 Statistical analysis 
To describe the characteristics of two treatment groups, mean values and standard 
deviations were used. T-test and Fisher’s exact test were used to assess equality between 
the treatment groups at baseline and at 12-month follow-up. The normality of the variables 
was tested with Kolmogorov-Smirnov test. In variables with a right skewed distribution; a 
logarithmic transformation was applied before the analysis. Geometric means and 
confidence intervals (CI) were reported for these variables. The statistical significance of 
differences in changes between the groups was assessed with t tests, and additionally by 
analysis of covariance (ANCOVA) with adjustment for age and sex. For non-parametric 
variables, Wilcoxon test was used. Recovery from OSA was analyzed with a logistic 
regression model, adjusting for baseline differences in age, sex, BMI, and AHI between the 
groups. The differences in risk are reported as odds ratios with 95% confidence intervals. 
All comparisons between the treatment groups were based on the intention-to-treat 
principle. Power analysis was originally calculated to detect the improvement of AHI 
where the study sample size was estimated to achieve 90% power at a 5% significance level 
to detect 25% lower prevalence of mild OSA at follow-up in the intervention group as 
compared with the control group. This calculation was made under the assumption that 
there would be no improvement in mild OSA in the control group. In the secondary 
analysis of continuous variables between the OSA and non-OSA-group, the unequal 
sample size had a power of 80% and a statistical significance of 0.05 to detect the effect size 
of 0.54 between the groups in BRS an FMD values and 0.64 between the groups in FMD 
change. In order to determine predictors of FMD, Spearman’s univariate correlations and 
multiple linear regression models were used.   Bonferroni correction was used in table 5 to 
adjust for multiple comparisons, and two tail P values < 0.003 were considered statistically 
significant.  All characteristics and variables were analyzed with the Statistical Package for 
Social Sciences program (SPSS software, version 19 for Windows; SPSS Inc, Chicago, IL). 
4.6 ETHICAL ASPECTS 
The studies were approved by the Research Ethics Committee of the Hospital District of 
Northern Savo, Kuopio, Finland (17.8.2004, decision number 127/04. Written concent were 
signed by the patients after they were given oral and written information about the trial 
protocol.  
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5 Results 
The cross-sectional data of patients with mild OSA at baseline were analyzed by including 
predictors of cardiovascular disease in the comparison with the habitual snorers without 
OSA (study I ). In the randomized controlled intervention study, the data of patients with 
mild OSA were analyzed to assess whether lifestyle intervention would improve 
cardiovascular risk factors (study II). There were five drop-outs in the intervention group 
and four in the control group, i.e. 34 and 35 patients completed the 1 year follow up, 
respectively. Study III explored which factors, particularly those related to nasal resistance, 
could explain the missing effect of successful weight loss.  
5.1 PREDICTORS OF CARDIOVASCULAR DISEASE 
5.1.1 Cross-sectional baseline comparison of patients with mild OSA and weight-
matched non-OSA snorers 
Brachial artery diameter at rest, its flow-mediated vasodilatation as well as the response to 
glyceryl trinitrate administration were almost identical in these two groups. Furthermore, 
only in 23 % of subjects in the OSA group and in 38 % of non-OSA snorers was FMD% <50 
% of the gender specific reference value (non significance between the groups).(Juonala et 
al. 2008) Absolute BRS values (9.97 ± 6.70 vs. 10.51 ± 7.16) as well as the BRS values, when 
estimated proportional to age and sex related reference values, were almost the same in 
these groups. Furthermore, 6.2 % of subjects in the OSA patients and 2.1 % of non-OSA-
snorers had BRS% <50 % of the gender specific reference value (NS). Unfortunately, 
although the baseline cross-sectional control group of non-OSA snorers was weight-
matched, patients with OSA were slightly but significantly older than control subjects 
(P=0.02) and there were significantly more males in the OSA group (P=0.03). Table 1 shows 
the characteristics of the study population. The BMI, blood pressure, fasting glucose, 
insulin, lipid levels and the time interval between the sleep and the ultrasound studies were 
comparable in the OSA patients and non-OSA snorers.  
 
Table 1. Clinical characteristics of the study population at baseline in OSA and non-OSA groups. 
The data represent mean values with standard deviations (SD), frequencies or medians with range 
(min, max). 
   
Parameter 
 OSA 
N=81 
Non-OSA 
snorers, N=48 P  
Age, years 50 (9)  46 (11) 0.02  
Sex (male/female) 60/21 27/21 0.03 
BMI, kg/m2 32.5 (3.0) 31.7 (3.7) 0.17 
Systolic blood pressure 
(mmHg) 130 (11) 132 (12) 0.40 
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Diastolic blood pressure 
(mmHg) 81 (8)   83 (10) 0.72 
Fasting plasma glucose 
(mmol/l) 6.2 (1.9) 5.9 (1.1) 0.37 
Fasting serum insulin 
(mU/l) 12.1 (6.0) 11.6 (5.7) 0.68 
Fasting serum cholesterol 
(mmol/l) 4.7 (0.8) 5.0 (0.9) 0.06 
Fasting serum HDL-
cholesterol (mmol/l) 1.1 (0.3) 1.2(0.4) 0.02 
Fasting serum 
triglycerides (mmol/l) 1.7 (1.1) 1.5 (0.9) 0.32 
Hypertension  (n) 34 13 0.07 
Antihypertensive 
medication (n) 38 17 0.14 
Hypercholesterolemia 
medication (n) 26 5 0.00 
Coronary artery disease 
(n)  3 0 0.24 
Diabetes (n) 7 2 0.28 
Current smoker, n 21 11 0.44 
Apnea hypopnea Index 
(AHI) 9.3 (3.3) 1.9 (1.4) 0.00 
Average oxygen 
saturation (%) 94.0 (1.4) 94.8 (1.7) 0.02 
Time with oxygen 
saturation lower than 
90% (min) 4.6 (0.4, 304.0) 1.8 (0.1, 337.0) <0.01 
Time with oxygen 
saturation lower than 
90% (%) 1.0 (0.1, 46.06) 0.4 (0.1, 63.4) 0.04 
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T-test for continuous variables, Fisher’s extract test for continuous variables.  *ANCOVA adjusted for age 
and sex 
 
In a further analysis, patients who had OSA combined with a decreased FMD% had also 
elevated fasting insulin levels, higher BMI values, decreased HDL-cholesterol levels as well 
as lower average oxygen saturation when compared with OSA subjects with well-
preserved FMD% .  
 
Table 2. Clinical characteristics in subjects with and without OSA. The data represent mean values 
with standard deviation (SD),frequencies or medians with range (min, max). 
 
 Group, (SD)  
Parameter OSA, N=81 
non-OSA 
snorers, N=48 P  
Flow-mediated 
vasodilatation: 
    
Diameter change (mm) 0.2 (0.1) 0.3 (0.2) 0.71     
FMD% 6.6 (0.0, 17.6) 6.5 (0.7, 60.9) 0.67 
FMD in relation to  
the reference value (%) 85 (48) 96 (127) 0.46 
Vasodilatation with 
exogenous nitric oxide: 
    
Diameter change (mm) 0.6 (0.2) 0.6 (0.2) 0.89 
NTG% 16.5 (5.8) 17.2 (5.9) 0.52 
Baroreflex sensitivity in 
phenylephrine 
test (mmHg/s) 9.97 (6.70) 10.51 (7.16)  0.67 
Percentage of the age 
and sex related  
reference value 91.4 (22.7) 92.2 (21.8) 0.84 
P: P value from logistic regression analysis for dichotomous variables, ANCOVA for continuous variables; 
adjustment for age and sex. BMI=body mass index, HOMA-IR=the homeostasis model assessment of 
insulin resistance,  HDL= high-density lipoprotein, ALT=alanine aminotransferase, AHI=apnea hypopnea 
index, SaO2= oxygen saturation. †Adjusted for age. ‡Adjusted for sex. 
 
In the OSA group, it was found that FMD% was directly correlated with female sex 
(r=0.354, P<0.01), fasting plasma HDL-cholesterol (r= 0.233, P<0.05) and inversely correlated 
with fasting glucose (r= -0.284, P<0.05) and insulin levels (r= -0.311, P<0.01). Furthermore, in 
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the OSA group, brachial artery diameter was inversely correlated with female sex (r=-
0.435,P<0.01), and average oxygen saturation (r=-0.244, P<0.05), whereas it was directly 
correlated with percentual time with oxygen saturation lower than 90% (r=0.242, P<0.05), 
BMI (r=0.239, P<0.05), fasting glucose (r=0.349, P<0.01) and insulin levels (r=0.254, P<0.05). 
In the group of non-OSA snorers, univariate analysis detected an inverse correlation 
between brachial artery diameter and age (r=-0.337, P<0.05) and fasting serum HDL 
cholesterol (r=-0.464, P<0.01). 
Linear regression analysis showed that in OSA patients, FMD% was positively 
associated with mean saturation (standardized beta coefficient =0.26, P=0.029), time with 
oxygen saturation under 90% (R=0.26, P=0.03) female sex (R=0.33, P=0.04) and insulin level 
(R=0.67, P=0.002). In a further multiple linear regression analysis, age, sex, AHI, BMI, mean 
systolic arterial pressure, fasting serum glucose level and total serum cholesterol level were 
added into the model, because of their known clinical importance. In this model, only age 
(P=0.03), female sex (P<0.01) and BMI (P=0.01) remained significantly associated with FMD.  
5.1.2 Follow-up study 
In spite of the randomization, the baseline BMI was significantly higher in the intervention 
group when compared to the control group. In addition, the diameter of the brachial artery 
was significantly larger and NTG% was significantly smaller in the intervention group than 
in the control group. There were no significant differences in other relevant baseline 
variables between the groups. In the lifestyle intervention group, weight decreased by 10.4 
kg during the 12 months’ study period. In the control group, the change in weight during 
the 1-year follow-up was -1.9 kg. The change between the groups was statistically 
significant. In the intervention group, significant improvements were observed in mean 
AHI, in time with mean saturation below 90% and in mean saturation compared with the 
control group. Furthermore, BMI, weight, serum triglycerides and plasma fasting insulin 
improved significantly in the intervention group in comparison with the control group. 
When correction for multiple comparisons was made, only changes in mean saturation, 
plasma fasting insulin, BMI and weight remained statistically significant (Table 3). 
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Table 3. Changes over the 12-month follow-up. The data represent mean changes with 95% 
confidence interval [CI]. 
 Control Group     
 
(CI) 
(n=37) 
Intervention Group 
(n=35)  P 
   
AHI (total) events/h -0.21 (-2.8-2.4) -3.95 (-5.9-(-2.0))*** 0.02 
   
Time with mean SaO2 
>90%  (min) 2.64 (-4.4-9.7) -15.92 (-38.9-7.1)* 0.04 
   
Mean oxygen 
saturation (%) -0.29 (-0.8-0.2) 0.83 (0.4-1.3)*** <0.01## 
   
Brachial artery 
diameter at rest (mm) 0.40 (-0.2-0.3) -0.19 (-0.4-(-0.2))* 0.10 
   
Flow mediated 
vasodilatation FMD % 
(%) 0.18 (-1.3-1.6) 0.45 (-0.9-1.8) 0.78 
   
Dilatation amplitude in 
FMD-test (mm) -0.06 (-0.4-0.7) -0.11 (-0.4-0.6) 0.34 
   
NTG% (nitric oxide) -2.09 (-0.2-0.3)* 0.12(-0.3-<0.0) 0.11 
   
Plasma fasting glucose 
(mmol/l) -0.36 (-0.9-0.1) -0.65 (-1.4-0.1) 0.53 
   
Plasma fasting insulin 
(mmol/l) -1.11 (-2.4-0.1) -6.00 (-8.6-(-3.3))*** <0.01## 
   
Serum cholesterol 
(mmol/l) 0.134(-0.1-0.3) -0.10 (0.4-0.2) 0.19 
   
Serum HDL cholesterol 
(mmol/l) 0.06 (<-0.0-0.1) 0.134 (0.6-0.2)** 0.14 
   
Serum triglycerides 
(mmol/l) -0.04 (-0.3-0.2) -0.48 (-4.1-(-2.8))* 0.05 
   
BMI (kg/m2) -0.63 (-1.3-0.2) -3.47 (-4.1-(-2.8)*** <0.01## 
   
Weight (kg) -1.85 (-3.7-<0.0) 
-10.38 (-12.5-(-
8.3))*** <0.01## 
   
    
   
Asterisks indicate whether the change between follow-up and baseline was statistically significant: 
*P<0.05, **P<0.01 and ***P<0.001; paired-samples t-test. Independent-samples t-test for 
changes, Wilcoxon test for nonparametric variables. Bonferroni correction was used to adjust 
multiple comparisons, and two tail P values < 0.003 were considered significant. ## P<0.003 
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At the 12-month follow-up, although there were no statistically significant differences 
between the groups, the brachial artery diameter in the intervention group had improved 
significantly from baseline. The dilatation response to exogenous nitric oxide (NTG%) 
decreased significantly in the control group even though no significant differences between 
the groups were found (Table 3). 
5.2 NASAL RESISTANCE AND SUCCESFUL WEIGHT REDUCTION 
During the 12 month follow-up, a total of 26/52 patients succeeded in achieving ≥5 % 
weight reduction and of those, 16 improved their AHI to under 5 events/hour, and thus, 
were considered to be cured from OSA. However, despite the successful weight reduction, 
the AHI of 10/26 remained at ≥5 events/hour.  Clinical findings between the OSA and non-
OSA groups did not differ significantly e.g. in terms of nasal polyposis, septal deviation or 
nasal congestion evaluated by clinical examination both at the baseline and at 12-month 
follow-up visit. At baseline, AHI was significantly higher in the apnoeic group compared to 
the non-OSA group, whereas the improvement of AHI at the follow-up was significantly 
greater in the non-OSA group. Furthermore, in the OSA group, 40% (4/10) of the patients 
were cigarette smokers, whereas in the non-OSA group 19% (3/16) of the patients were 
smokers. One patient from the non-OSA group managed to quit smoking during the 
follow-up, but none succeeded from the OSA group.  
5.2.1 Rhinometric measurements  
At the 12-month visit, non-OSA group displayed significantly less nasal resistance in the 
supine position (0.14 Pa/cm3/s) than the patients of the OSA group (0.29 Pa/cm3/s, P=0.006). 
The mean changes in nasal resistance during the 12-month follow-up in the non-OSA group 
and in the OSA group were -0.13 Pa/cm3/s and 0.01 Pa/cm3/s (P=0.006) respectively. At 12 
months, the effect of nasal decongestion in the supine position was significantly more 
intense in the OSA group (-0.13 Pa/cm3/s) compared to the non-OSA group (-0.03 Pa/cm3/s, 
P = 0.02). Furthermore, the subjects in the OSA group displayed a greater mean change due 
to nasal decongestion in the follow-up period compared to those in the non-OSA group (P = 
0.03) (Table 4). 
The correlation between the change in BMI and the change in nasal resistance was 
borderline statistically significant with the current sample size (Pearson correlation 
coefficient r=0.262, P=0.07).  
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Table 4. Rhinomanometric measurements in supine position. Asterisks indicate whether the change 
between follow-up and baseline was statistically significant: *p<0.05, **p< 0.01; paired samples t-
test. Independent samples t-test, or ANCOVA for changes, adjusted for baseline. 
 
Parameter 
 
OSA 
(n=10) 
non-OSA snorers 
(n=16) 
Significances 
P 
Mean total nasal inspiratory 
resistance 
 
Baseline 0.28 (0.15) 0.27 (0.12) 0.88 
12 months 0.29 (0.18) 0.14 (0.08) 0.006 
Change 0.01 (0.25) -0.13* (0.20) 0.006 
 
Mean total nasal inspiratory 
resistance decongested 
Baseline 0.25 (0.08) 0.22 (0.05) 0.51 
12 months 0.17 (0.09) 0.12 (0.06) 0.07 
Change -0.08*  (0.11) -0.11** (0.11) 0.51 
Effect of nasal decongestion 
Baseline -0.03 (0.14) -0.05 (0.18) 0.52 
12 months -0.13 (0.14) -0.03 (0.07) 0.02 
Change -0.10(0.20) 0.02 (0.18) 0.03 
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5.2.2 Symptom questionnaires 
In MiniRQLQ, both groups reported mild impairment in QOL and nose related symptoms. 
The total miniRQLQ score was 15.0 in the non-OSA group and 19.3 in the OSA group at the 
12-month visit. There was no significant change between the baseline and 12 month 
measurements in miniRQLQ. 
5.2.3 Effect of smoking  
In a further analysis, when the 26 patients with a significant weight loss were divided into 
smokers (N=7) and non-smokers (N=19), the mean change in nasal resistance after the 
weight loss was 0.06 Pa/cm3/s in smokers and 0.12 Pa/cm3/s in non-smokers (P =0.009). 
Furthermore, the mean change in AHI in cigarette smokers compared with non-smokers 
was -1.4 and -6.0, respectively ( P = 0.035). 
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6 Discussion 
The present study has its origin in observations of patients with mild OSA and the natural 
tendency of mild OSA to worsen over time. It is well-documented that severe OSA is 
associated with major macrovascular morbidity and mortality (Punjabi et al. 2009, Muraja-
Murro et al. 2013a). However, it is not yet fully understood at what stage of OSA, the 
microvascular complications start to appear. This is of importance, since recently 
convincing evidence has appeared that long-term adherence to a healthy lifestyle along 
with weight reduction can result in marked improvement of OSA and that this can be 
detected as long as four years after the active intervention, i.e. the intervention was able to 
prevent the unwanted progression of OSA towards the more severe stages and 
cardiovascular consequences (Tuomilehto et al. 2013). The present study explored the 
cardiovascular risk factors in mild OSA. Lifestyle intervention with weight reduction is an 
efficient treatment modality in the majority of overweight OSA patients. However, for 
those patients who do not improve their OSA despite the successful weight loss, it was 
considered necessary to explore the factors related to nasal breathing that might explain 
why weight reduction did not achieve a curable effect in OSA. 
In short, the present study shows that in mild OSA, the risk factors for cardiovascular 
disease are not yet present at least in terms of endothelial dysfunction and baroreflex 
sensitivity. In addition, lifestyle intervention with weight reduction is an effective treatment 
modality in overweight patients with mild OSA. Furthermore, impaired nasal breathing 
and smoking may explain why patients who despite achieving a successful weight loss, 
were not cured of OSA. 
6.1. ENDOTHELIAL DYSFUNCTION 
The present study did not detect evidence of endothelial dysfunction in mild OSA patients, 
i.e. was no correlation between AHI and FMD. However, the average oxygen desaturation 
was lower in patients with impaired FMD. It seems that there are some controversies 
related to the association between mild SDB and endothelial dysfunction. Some studies 
have observed a preserved endothelial function in mild OSA patients (Chung et al. 2007, 
Sert Kuniyoshi et al. 2011). However, there have also been reports of endothelial 
dysfunction in patients with mild SDB (Nieto et al. 2000, Vita, Keaney 2002, Faulx et al. 
2004, Oflaz et al. 2006). In cases of moderate to severe OSA, more evident endothelial 
dysfunction has been found (Bayram et al. 2009, Kato et al. 2000, Oflaz et al. 2006, Patt et al. 
2010, Ip et al. 2004, Sert Kuniyoshi et al. 2011, Kohler et al. 2008a, Chung et al. 2009).  Based 
on the current results, in patients with mild OSA, the disease may not be severe enough to 
evoke marked endothelial dysfunction. This is also supported by the recent epidemiological 
studies that have revealed OSA to be an important risk factor for increased mortality, 
particularly due to coronary artery disease, but only in those patients with severe OSA 
disease (Punjabi et al. 2009). 
It has been shown that endothelial dysfunction may also commence in patients with 
other cardiovascular risk factors such as hypertension, diabetes mellitus, hyperlipidemia, 
obesity, and in smokers even before the signs of atherosclerosis develop. In addition, 
endothelial function can be restored by treating OSA or other risk factors (Clarkson et al. 
1996, Gokce et al. 2001, Tounian et al. 2001). These findings support the consensus 
statement on OSA and metabolism issued by the International Diabetes Federation which 
emphasized that in both clinical and scientific work, the association between type 2 
diabetes, cardiometabolic syndrome and OSA should firmly be kept in mind. 
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In the present study, the overweight patients with OSA had decreased mean oxygen 
saturation values and their parameters of metabolic function were impaired, although their 
endothelial function remained unchanged. This could be interpreted that although some 
signs of elevated risks for cardiovascular complications were present, the hypoxemia may 
not have been profound enough to evoke endothelial dysfunction. It is well-documented 
that OSA can progress from mild SDB to more severe OSA over a varying period of time, 
but that this may be surprisingly short if it is accompanied by weight gain and the lack of 
effective treatment (Berger, Berger & Oksenberg 2009, Sahlman et al. 2007). This highlights 
the importance of lifestyle intervention with weight reduction, since it was observed to lead 
to significant improvement of both OSA and metabolic parameters.  
6.2 BAROREFLEX SENSITIVITY 
The main finding of this study was that baroreceptor sensitivity measured by i.v. 
phenylephrine test during wakefulness is not impaired in mild OSA patients when 
compared to non-OSA- snorers. Only 6.2% of OSA and 2.6% of non OSA snorers presented 
evidence of impaired BRS. In our study BRS in mild-OSA and non-OSA snorers averaged 
9.97 ±6.7 and 10.51 ±7.16 respectively. This is in line with the BRS values of healthy 
individuals of the same age group (Laitinen et al. 1998). In literature, BRS values in patients 
with asymptomatic coronary artery disease average 7.8±5.4 (Simula et al. 2013) and the BRS 
values of type II diabetes patients averaged 6.8±2.9 (Loimaala et al. 2003). 
Sympathetic activation is considered to be one of the key mechanisms linking OSA to 
cardiovascular morbidity and mortality (Narkiewicz et al. 1998b, Narkiewicz et al. 1999, 
Imadojemu et al. 2007). It has been shown that even mild OSA is associated with increased 
activation of the inflammatory system, however this can be normalized by achieving a 
weight loss such as via a successful lifestyle intervention (Tuomilehto et al. 2010, Sahlman 
et al. 2010). However, at present, there is only limited information available describing at 
what stage of OSA the impairment of cardiac autonomic regulation appear. Decreased BRS 
is considered to be one of the early markers of autonomic dysfunction in several diseases 
such as hypertension (La Rovere et al. 1998), diabetes (Frattola et al. 1997)chronic heart 
failure (Mortara et al. 1997) and coronary artery disease (La Rovere et al. 2001). BRS 
measured by the phenylephrine method is known to have clear prognostic value in 
predicting mortality in many cardiovascular diseases (La Rovere et al. 1998, Farrell et al. 
1992, Farrell et al. 1991). Therefore this method was applied in the present study to  assess 
BRS as it has recognized strengths in cardiovascular risk stratification (Goldberger et al. 
2008, La Rovere et al. 2011). One of the weaknesses of this method is that, since it entails the 
intravenous administration of phenylephrine, it cannot be applied during sleep. 
The results of earlier studies on BRS in OSA have been somewhat contradictory. The 
present finding that BRS does not differ between the OSA and non-OSA snorers is in line 
with the previous study of Ryan et al. (Ryan et al. 2007). BRS assessed by a sequence 
method during sleep, was not impaired in mild or moderate OSA when compared to severe 
OSA. Correspondingly, no impairment of BRS was found in severe OSA in the study of 
Narkiewitch and co-workers who also measured BRS by the phenylephrine test during 
wakefulness (Narkiewicz et al. 1998a). However, also contradictory findings have been 
reported. Ward and co-workers found that BRS was impaired during wakefulness in 
subjects with severe OSA when using the sequence technique, a spectral transfer function 
technique and an alpha index technique (Ward et al. 2006). Similar results showing 
decreased BRS in patients with OSA have been observed also in studies in which BRS 
assessments were performed with the Valsalva technique (Noda et al. 2007) and with the 
nitroprusside test (Carlson et al. 1996). Studies performed with the sequence method have 
shown that nocturnal BRS is reduced in severe OSA. (Parati et al. 1997, Ryan et al. 2007, 
Bonsignore et al. 2006).  Some studies have demonstrated reduced BRS even in non-OSA 
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snorers (Gates et al. 2004, Mateika, Kavey & Mitru 1999). In addition, there are several 
studies demonstrating that CPAP treament improves BRS in OSA patients (Bonsignore et 
al. 2006, Kohler et al. 2008b).  However, it is difficult to make direct comparisons between 
these previous studies and the present study, because in the above trials different methods 
and/or patients with more severe OSA were employed. 
In conclusion, BRS was found to be well preserved in patients with mild OSA. This 
highlights the importance of an early detection and supports the proposal that in the early 
stages of OSA, the disease may still be curable before the permanent complications have 
become established. 
6.3 LIFESTYLE INTERVENTION AND ENDOTHELIAL DYSFUNCTION 
Weight reduction is an effective treatment for OSA and weight loss is recommended in all 
clinical guidelines for treating OSA when it is accompanied with obesity (Tuomilehto et al. 
2009, Foster et al. 2009, Johansson et al. 2009). In the present study, the intervention did not 
result in significant improvements of FMD between the study groups. The normal variance 
of FMD was comparatively high and therefore the sample size was perhaps too small to 
detect significant changes between the study groups.  
In agreement with previous studies, (Wycherley et al. 2010, Clifton et al. 2005) the weight 
reduction did not result in an improvement of FMD in the 1-year follow up. Possibly, 
significant improvements in FMD could have been detected if the sample size would have 
been larger (Corretti et al. 2002). In addition, in studies with shorter follow-up times, some 
improvements in FMD after the weight reduction have been detected (Ades et al. 2011, 
Hamdy et al. 2003).Here, impaired FMD was significantly associated with the metabolic 
parameters related to impaired glucose and lipid metabolism. This correlation was found 
only in OSA patients. These findings are similar to the previous results described in older 
OSA patients, (Nieto et al. 2004) patients with metabolic syndrome (Angelico et al. 2011) 
and in patients with hyperglycaemia (Caballero et al. 1999).  
6.4 IMPAIRED NASAL BREATHING AND LIFESTYLE INTERVENTION IN 
MILD OSA 
The present study suggests that impaired nasal breathing might be either one factor 
preventing the beneficial effect of weight loss in overweight patients with mild OSA or a 
result of OSA. At the 12-month follow-up, those patients still having OSA despite the 
successful weight reduction had a significantly higher nasal resistance compared with the 
patients who were objectively cured from OSA. This suggests that impaired nasal breathing 
may be one factor preventing the beneficial effect of weight loss in overweight patients with 
mild OSA. On the other hand, the decrease in nasal resistance in patients who were cured 
from OSA may be due to the improvement of nasal inflammation which is present in OSA. 
Recent studies have suggested that higher nasal resistance is rather a result than a cause of 
OSA, since nasal resistance was reduced after UPPP and tonsillectomy procedures when 
these procedures lead to the improvement of AHI (Lu et al. 2014, Nakata et al. 2007). 
Previously smoking has been found to exert adverse effects on the nasal airway. It has 
been associated with several symptoms i.e. with increased snoring, blocked nasal breathing, 
and pharyngeal soft tissue volume. Overall, the combination of cigarette smoking and 
altered nasal function seem to compromise the lower airways and thus, predispose to sleep 
disordered breathing (Virkkula et al. 2007, Virkkula et al. 2005). The effects of cigarette 
smoking on the nasal airway remain mostly an unknown issue, thus they might possibly be 
secondary to mucosal inflammation (Kjaergaard, Cvancarova & Steinsvaag 2010). In the 
present study, an adverse effect was also observed of cigarette smoking on nasal breathing. 
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In non-smokers, nasal resistance improved after the lifestyle intervention, whereas it 
tended to increase in smokers and in addition, AHI improved more in non-smokers. Since 
there were more smokers in the OSA-group (40%) compared with the non-OSA group 
(19%), it is possible that cigarette smoking partly prevented the beneficial effects of weight 
reduction on OSA.  
In the present study, no correlation between AHI and nasal resistance was found in 
either of the groups. The previous data on the effect of nasal breathing on OSA is 
conflicting since there is no agreement on whether or not there is any correlation between 
nasal resistance and OSA (Lofaso et al. 2000, Li et al. 2005, Miljeteig, Hoffstein & Cole 1992, 
Yagi et al. 2009). Furthermore, the findings on the correlation between nasal breathing and 
OSA in different weight groups have also been controversial; in one study, significant 
correlations between AHI and nasal resistance were detected only in obese patients (Tagaya 
et al. 2010), while in another study the correlation was observed only in non-obese patients 
(Virkkula et al. 2003). 
Only a few studies have explored the relationship between obesity and nasal resistance. 
A correlation between subjective feeling of nasal blockage and obesity was observed in one 
population based study (Johansson, Bende 2007). On the other hand, in a study 
investigating young healthy adults, BMI was found not to exert any effect on nasal 
resistance (Numminen et al. 2002). In addition, a previous study evaluating the effects of 
intensive weight reduction on rhinomanometric measures was unable to detect any 
correlation between changes in BMI and nasal resistance (Kemppainen et al. 2008).  In the 
present study, only a borderline correlation was found between BMI and rhinomanometric 
measurements. However, this is most likely due to the small sample size in this study, as 
the correlation coefficient was rather high. 
6.5 LIMITATIONS 
There are some limitations to this study. Endothelial function was measured in the conduit 
artery level using the non-invasive brachial artery test and ultrasound imaging, but not at 
the peripheral arterial level. Most of the well-conducted earlier studies evaluating the 
association between OSA and BRS have included fewer patients, and usually the study 
groups have been more heterogeneous in terms of the degree of OSA. Therefore, one could 
argue that the present study, despite some of its weaknesses, does provide new important 
information about microvascular conditions present in the early stages of OSA. 
Unfortunately, in baseline cross-sectional analyses, the non-OSA snorers and OSA patients 
were only weight-matched, not age and sex matched as well. This could possibly been 
achieved if the group size of OSA and non-OSA snorers had been equal. Unfortunately, it 
was not executable in a single center setting. Furthermore, in the follow up study, although 
randomized at baseline, the intervention group was heavier than the control group. This 
fact among with the comparable small study population, especially when the standard 
deviation of BRS was comparable high, could degrade the reliability of multivariate 
analysis in this model. Furthermore, since this intervention was conducted in patients with 
mild OSA, the findings may not be directly generalizable to all OSA patients. Nonetheless, 
it does seem that this is the first study with a randomized design to have examined the 
association between endothelial function and untreated mild OSA. Most of the well-
conducted earlier studies on the association between OSA and endothelial function have 
included fewer patients, and usually the study groups have been more severe or more 
heterogeneous in terms of the degree of OSA. Therefore, in the search for better clinical 
guidelines, it is one conclusion of this thesis that despite some of its weaknesses, the new 
results do provide new important insights into the link between mild OSA and 
cardiovascular complications. 
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7 Conclusions 
 
The findings of the present study were 
 
1. In mild OSA, endothelial function was found to be preserved 
2. In mild OSA, the baroreflex sensitivity was still preserved.  
3. Impaired nasal breathing may prevent the beneficial effect of weight reduction in 
overweight mild OSA patients and cigarette smoking may exert a negative effect on 
both nasal resistance and on the improvement in the AHI values. 
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